S
evere acute respiratory syndrome (SARS), an emerging infectious disease of humans, appeared in China in November 2002 and spread to 30 countries in early 2003. Before the epidemic ended, 8,098 probable cases of SARS and 774 associated deaths were reported to the World Health Organization (www.cdc.gov͞mmwr͞mguidesars.html). The etiologic agent of SARS was identified as a coronavirus (CoV) (1) (2) (3) (4) and the genome sequence established it as a new member of the family (5, 6) . Closely related CoVs were recovered from civet cats and other animals in southern China, although the source of human SARS infections is uncertain (7) . Other members of the CoV family can cause fatal diseases of livestock, poultry, and laboratory rodents (8) . The two previously identified human CoVs, however, cause only mild upper respiratory infections (8) .
All CoVs encode a common set of structural components that include a nucleocapsid protein and three integral membrane proteins, namely the transmembrane protein, the envelope protein, and the spike protein (S) (9, 10) . The latter is a type-I transmembrane glycoprotein, which forms the characteristic corona of large protruding spikes on the virion surface and mediates binding to the host cell receptor and membrane fusion. In previously studied CoVs, S was shown to be an important determinant of pathogenesis as well as the major target of protective immunity (8, 11) . The SARS-CoV S is quite divergent from those of other CoVs, exhibiting only 20-27% overall amino acid identity (5) . Recent studies indicated that the SARS-CoV S is expressed as a noncleaved glycoprotein with an apparent mass of 180-200 kDa that interacts with a functional receptor identified as angiotensin-converting enzyme 2 (12, 13) .
Although the 2002͞2003 epidemic was eventually controlled by case isolation, the high morbidity and mortality, lack of specific treatment, and potential of reemergence make it imperative to develop effective means to prevent or cure the disease should it reappear. As an initial step, a rodent animal model was developed in which SARS-CoV replicates but does not cause disease (14) . Importantly, prior infection or transfer of convalescent serum prevented replication of SARS-CoV in the respiratory tract of mice. The purpose of the present study was to determine whether expression of the S alone could raise neutralizing antibodies and protectively immunize mice.
Vaccinia virus vectors, including the highly attenuated modified vaccinia virus Ankara (MVA) strain, have been used to express and characterize glycoproteins of numerous pathogens, and some of those are being evaluated as candidate prophylactic and therapeutic vaccines (15). MVA accumulated multiple deletions and other mutations during Ͼ500 passages in chicken embryo fibroblasts (CEFs) (16) (17) (18) , resulting in a severe host range restriction in most mammalian cells (19) (20) (21) . Because the restriction occurs at a late stage of virus assembly, MVA expresses viral and recombinant proteins in nonpermissive as well as in permissive cells (22) . MVA is highly attenuated due to its replication defect in mammalian cells, and no adverse effects were reported even when high doses of MVA were given to immune deficient nonhuman primates (23) or severe combined immunodeficiency disease mice (24) . Here, we show that the full-length S of SARS-CoV, expressed by MVA, induces binding and neutralizing antibody and protectively immunizes mice against a subsequent infection with SARS-CoV.
Materials and Methods
Viruses and Cells. Primary CEF cells prepared from 10-day-old embryos were grown in minimum essential medium supplemented with 10% FBS and was used to propagate and titer MVA and recombinant MVA strains.
Recombinant Virus Construction. The 3,768-nt ORF encoding the SARS-CoV S of the Urbani strain was copied and amplified from SARS-CoV virion RNA by RT-PCR, and was cloned and sequenced. A clone was identified that exactly matched the published sequence (GenBank accession no. AY278741). Two poxvirus transcription termination motifs (TTTTTNT) in S were altered by using the QuikChange multisite-directed mu-tagenesis kit (Invitrogen). After mutagenesis, the entire S gene was PCR-amplified with or without an influenza virus hemagglutinin (HA) epitope tag and inserted into the XmaI site of the pLW44 transfer vector (provided by L. Wyatt, National Institutes of Health), bringing it under the control of the vaccinia virus modified H5 early late promoter (25) and adjacent to the gene encoding enhanced GFP regulated by the vaccinia virus P11 late promoter. The correct sequence of the entire S DNA insert was confirmed and recombinant MVAs were made by transfecting transfer plasmids into CEF that were infected with 0.05 plaque forming units (pfu) of MVA per cell. Florescent plaques were cloned by six successive rounds of plaque isolation, propagated in CEF, and purified by sedimentation through a sucrose cushion (26) . Titers of MVA͞S and MVA͞S-HA were determined by staining plaques with anti-vaccinia virus rabbit and anti-HA mouse antibodies, respectively.
Western Blotting. CEF and HeLa cells were infected with 5 pfu of recombinant MVA for 18 h. Infected cells were lysed in ice-cold RIPA buffer [50 mM Tris⅐HCl (pH 7.5)͞150 mM NaCl͞1% Triton X-100͞0.1% SDS͞0.5% sodium deoxycholate] supplemented with protease inhibitor mixture (Sigma). Lysates were kept on ice for 10 min, were centrifuged, and were resolved by SDS͞PAGE on a Bistris [bis(2-hydroxyethyl)amino]tris(hydroxymethyl)methane 4-12% polyacrylamide gel. Proteins were transferred to a nitrocellulose membrane, blocked with 5% skimmed milk in PBS, and incubated for 1 h at room temperature with anti-HA mouse mAb (Covance Research Products, Berkeley, CA) or anti-SARS-CoV S rabbit polyclonal antibody (IMG-541, Imgenex, San Diego) diluted 1:1,000 or 1:500 in blocking buffer, respectively. The membrane was washed in PBS containing Tween-20 (0.1%) and was incubated for 1 h with horseradish peroxidase-conjugated anti-mouse and anti-rabbit secondary antibody (Calbiochem) diluted 1:2,000. The membrane was washed and proteins were visualized with the Super Signal chemiluminescence substrate (Pierce). Confocal Microscopy. CEF or HeLa cells on coverslips were infected with 5 pfu per cell of MVA, MVA͞S, or MVA͞S-HA, incubated for 18 h, and were either left unfixed and unpermeabilized or fixed with cold 4% paraformaldehyde in PBS for 20 min at room temperature and permeabilized with 2.5% digitonin in PBS for 5 min on ice. The coverslips were washed and incubated with anti-SARS mouse serum kindly provided by L. Anderson (Centers for Disease Control, Atlanta) or anti-HA mouse mAb for 1 h at room temperature, were washed again, and were incubated with Alexa 594-conjugated-anti-mouse IgG (Molecular Probes) diluted in PBS containing 10% FBS for 30 min at room temperature. Coverslips were mounted in 20% glycerol and examined with an inverted confocal microscope.
ELISA.
A 96-well plate was coated overnight at 4°C with 50 ng per well of soluble recombinant protein containing the S1 domain of SARS-CoV S made in insect cells, blocked with 5% skimmed milk in PBS containing 0.2% Tween-20 for 1 h at 37°C, and incubated with two-fold dilutions of serum from unimmunized or immunized mice for 1 h at 37°C. After extensive washes, the plate was incubated for 1 h with horse radish peroxidaseconjugated secondary anti-mouse antibody (Roche Applied Science) diluted in blocking buffer, washed again and incubated with substrate solution (3,3Ј-5,5Ј-tetramethylbenzidine, Roche Applied Science). The difference in absorbance at 370 and 492 nm was determined, readings from wells lacking antigen were subtracted, and endpoint titers were calculated when the absorbance difference was Ͻ0.1.
Neutralization Assay. Neutralizing antibody was determined by the inhibition of cytopathic effects mediated by SARS-CoV on Vero cell monolayers as described (14) . The dilution of serum that completely prevented cytopathic effect in 50% of the wells was calculated (27) .
Animal Challenge Experiments. Groups of eight BALB͞c mice were inoculated intranasally (i.n.) or i.m. with 10 7 pfu of MVA or MVA͞S at 0 and 4 weeks. Four weeks after the second immunization, animals were challenged i.n. with 10 4 tissue culture 50% infective dose (TCID 50 ) of SARS-CoV as described (14) . Two days later, the lungs and nasal turbinates of four animals in each group were removed and the SARS-CoV titers were determined (14) .
To obtain serum for passive protection studies, two groups of eight BALB͞c mice received MVA͞S or MVA i.m. at 0 and 4 weeks. Three weeks after the last immunization, sera were collected and pooled. Undiluted or diluted MVA͞S or MVA serum in a total volume of 0.4 ml was injected i.p. in two to four naïve mice. Mice were bled the following day to determine their levels of SARS-CoV-specific neutralizing antibody, and then each was challenged with 10 5 TCID 50 of SARS-CoV and analyzed as above.
Results

Characterization of SARS-CoV S Expressed by Recombinant MVA.
A cDNA clone containing the entire ORF encoding SARS-CoV S was modified by introducing silent mutations that eliminated two poxvirus transcription termination signals and was placed under the control of a vaccinia virus early͞late promoter (mH5) and inserted by homologous recombination into the site of an existing deletion (del III) within the MVA genome to produce MVA͞S (Fig. 1A) . We also constructed a second recombinant virus, MVA͞S-HA, with a 9-aa HA epitope tag coding sequence at the end of the S ORF. In each case, the gene encoding GFP regulated by a vaccinia virus promoter was coinserted into the MVA genome to facilitate the screening and isolation of recombinant viruses by repeated plaque purifications. Both viruses replicated well in CEF, and the SARS-CoV S insert was genetically stable, as assayed by plaque immunostaining with Sspecific antibodies.
A protein doublet with an estimated mass of Ϸ200 kDa, significantly higher than the value of 135 kDa for the unmodified protein predicted from the nucleotide sequence, was detected by SDS͞PAGE of lysates of cells infected with MVA͞S and MVA͞ S-HA and Western blotting with polyclonal antibody to S or a mAb to HA (Fig. 1B and data for MVA͞S not shown). In addition, some S was trapped near the top of the gel, presumably due to aggregates or oligomers that were not dissociated by treatment with SDS and reducing agent at 100°C.
The SARS-CoV S has 23 potential N-linked glycosylation sites (5), the use of which could contribute to the mass of the protein determined by SDS͞PAGE. To evaluate this possibility, S expressed in HeLa cells was treated with PNGase F, which hydrolyzes all types of N-glycan chains. PNGase F treatment converted the 200-kDa doublet to a single sharp band of Ϸ160 kDa ( Fig. 2A) , which was still greater than the 135 kDa estimated from the gene sequence. However, differences of this magnitude between the theoretical mass and the mass estimated by SDS͞ PAGE are commonly found, and this discrepancy does not necessarily indicate that S contains additional posttranslational modifications.
Further experiments were carried out by using endo H, which digests the N-linked high-mannose carbohydrate side chains of glycoproteins that are synthesized in the endoplasmic reticulum, but not after conversion to a more complex form in the medial Golgi apparatus. Only a subpopulation of S was digested, because both the original size protein and a faster migrating one were detected (Fig. 2 A) . The latter had a slightly higher mass than the PNGase F-treated protein, which is consistent with N-acetylglucosamine residues remaining after hydrolysis by endo H. To determine the kinetics of acquisition of endo H resistance, cells infected with MVA͞S-HA were pulse-labeled for 10 min with [
35 S]methionine and [ 35 S]cysteine and were then chased in medium containing unlabeled amino acids. At each time point, the epitope-tagged S protein was isolated by using an HA mAb affinity matrix; one portion was analyzed directly by SDS͞PAGE and autoradiography and an equal portion was first digested with endo H. Immediately after the pulse, we detected a sharp 200-kDa band that became more diffuse during the chase and was resolved as a doublet by 60 min in the absence of endo H treatment (Fig. 2B) . The pulse-labeled S was completely digested to a 160-kDa species by endo H (Fig. 2B) . A faint endo H-resistant band appeared by 40 min of chase (seen as a diffuse band in this particular experiment), indicating that a small fraction of S had become resistant to digestion (Fig. 2B) . Even after 80 min, however, there was still considerable endo Hsensitive S. The glycosylation and partial resistance to endo H was consistent with trafficking of the SARS-CoV S through the endoplasmic reticulum to the Golgi compartment. To determine whether S was expressed at the cell surface, unpermeabilized CEFs that had been infected with MVA͞S were stained with antibody to S followed by Alexa 594-conjugated-anti-mouse IgG. Whereas the fluorescence due to coexpressed GFP was present throughout the cytoplasm, the labeling of S was restricted to the cell surface (Fig. 3D) . Moreover, no labeling occurred in cells infected with the MVA vector (Fig. 3B ) or uninfected cells (data not shown). Experiments were also carried out with cells infected with MVA͞S-HA except that antibody to the epitope tag was used. The absence of staining of unpermeabilized cells (Fig. 3F) was consistent with the S protein having a type 1 topology with the tagged C terminus in the cytoplasm. After permeabilization of the plasma membrane with digitonin, both plasma membrane and juxtanuclear staining were evident (Fig. 3H ). Similar patterns were found when infected HeLa cells were examined by confocal microscopy (data not shown).
Immunogenicity of MVA͞S in Mice.
Mice were inoculated i.n. or i.m. with 10 7 pfu of MVA͞S at time 0 and again at 4 weeks. Antibody was determined by an endpoint ELISA using a recombinant protein consisting of the S1 domain of SARS-CoV made in insect cells and purified by affinity chromatography. Antibody was detected at 4 weeks and peaked at 6 weeks (Fig. 4A) . Similar titers were obtained after either route of inoculation. The titers began to decline with time and were not boosted at 2 weeks after the SARS-CoV challenge described in the next section (Fig. 4A) . The ability of sera to neutralize SARS CoV infectivity for VERO cells was determined as described (14) . Neutralizing antibody was detected after the second immunization by either the i.n. or i.m. route (Fig. 4B) .
Protection of Mice Immunized with MVA͞S.
Previous studies (14) demonstrated that mice inoculated i.n. with SARS-CoV exhibit no overt signs of disease, but have elevated virus titers in the respiratory tract that peak within 2 days and are cleared by 7 days. For the present study, we had three control and two experimental groups. The controls were mice that were uninoculated or that had received the MVA vector i.m. or i.n.. When these mice were challenged with 10 4 TCID 50 of SARS-CoV, Ϸ10 5 TCID50 of SARS-CoV per g of lung was recovered on day 2 (Fig. 5) . By contrast, the titers of SARS-CoV from the lungs of mice immunized with MVA͞S either i.m. or i.n. were reduced to levels that were barely above the limit of detection (Fig. 5) . Approximately 10 3 TCID 50 per g of SARS-CoV were recovered from the nasal turbinates of control mice, but this amount too was significantly reduced in the immunized animals (Fig. 5) . The severe reduction in SARS-CoV replication may explain the absence of an amnestic ELISA antibody response to S after challenge (Fig. 4A) . Neutralizing titers to SARS CoV were not measured after challenge.
Passive Protection Mediated by Serum from MVA͞S-Immunized Mice.
MVA can induce both humoral and cell mediated immune responses. To determine a role for antibody, we pooled sera from mice that had been immunized i.m. with 10 7 pfu of MVA͞S or MVA on day 0 and 28 and were bled 3 weeks later. The reciprocal ELISA titer to S1 was Ϸ1:25,000 and the mean neutralizing titer was 1:284. Undiluted or diluted serum (0.4 ml) was administered i.p. to naïve mice to evaluate the protective role of antibody. As a positive control, we administered hyperimmune SARS-CoV serum to two mice (14) . On the next day, the mice received an i.n. challenge of 10 5 TCID 50 of SARS-CoV, and 2 days later, their nasal turbinates and lungs were removed to measure the virus titers. Administration of undiluted MVA͞S serum reduced the lung titers by 10 5.1 (Table 1) , compared with recipients of MVA control serum, indicating that antibodies to the SARS CoV S conferred the observed protection. Protection was observed despite only achieving a neutralization titer of 1:35 in recipient mice. Replication of SARS-CoV increased as the quantity of passively transferred serum decreased, but significant reductions in lung virus titers still occurred at dilutions of 1:4, 1:16, and 1:64. The absence of detectable neutralizing antibody in mice receiving these dilutions of passively transferred serum probably reflects a low sensitivity of the in vitro neutralization assay, because the ELISA titers to S were Ͼ100-fold higher than the neutralization titers (Fig. 4) . The recovery of SARS-CoV from the nasal turbinates was also reduced, but to a relatively lesser extent than from the lungs.
Discussion
Our object was to express S in a native state to induce antibodies that would neutralize SARS-CoV. The secretory pathway of the cell has an important quality control function, and the trafficking of a protein from the endoplasmic reticulum to the plasma membrane is a sign of proper folding. The N-linked oligosaccharide pathway is frequently used for tracking protein movement. Addition of N-linked oligosaccharides occurs in the endoplasmic reticulum and the conversion of the high mannose form to complex endo H-resistant N-linked chains occurs on transport from the cis to the medial Golgi compartment. We found that the S ORF of SARS-CoV was expressed by recombinant MVA as a protein of Ϸ200 kDa, which was reduced to 160 kDa by a glycosidase specific for N-linked carbohydrates. Trafficking of S to the medial Golgi apparatus was indicated by acquisition of endo H resistance by a subpopulation of molecules within 40 min after pulse labeling. The staining of the surface of unpermeabilized cells infected with MVA͞S by S-specific antibody provided direct evidence for insertion into the plasma membrane. Furthermore, the inability of antibody to a Cterminal epitope tag to stain cells unless they were permeabilized indicated that S has a type 1 topology in the membrane. We did not detect putative S1 and S2 cleavage products, as found for group 2 but not group 1 CoV S proteins (28). Xiao et al. (13) expressed full-length S by transfection and detected low amounts of several smaller than full-length S fragments, which they suggested might include specific cleavage products, although no evidence to support this hypothesis was presented. Our characterization studies strongly suggested that MVA expressed a properly folded form of S, leading us to determine whether it would elicit neutralizing antibodies.
Mice immunized with MVA͞S by i.n. or i.m. routes developed antibodies that bound to the S1 domain of S and neutralized SARS-CoV in vitro. Furthermore, mice immunized i.m. or i.n. exhibited little or no replication of SARS CoV in the upper and lower respiratory tracts after an i.n. inoculation. Control mice vaccinated with the MVA vector by i.n. or i.m. routes were unprotected, indicating that the effect was specific for the expressed S protein and was not due to enhanced nonspecific immunity. The ability of i.m. or i.n. inoculation of a recombinant MVA to prevent upper and lower respiratory infections had previously been found in a rodent model of parainfluenza virus 3 (25) .
Previous studies (14) showed that i.p. inoculation of hyperimmune serum from mice inoculated twice with SARS CoV provided protection against SARS-CoV in the lower respiratory tract and to a lesser extent in the upper respiratory tract (14) . Protection with serum from MVA͞S-immunized animals was demonstrated in the present study. Because serum from animals inoculated with the MVA vector had no effect, we can attribute the protection to S-specific antibodies. These results indicated that the S of SARS CoV, like that of other CoV, is an important target of neutralizing antibody both in vitro and in vivo. Recently, mAbs specific to SARS-CoV S1 domain with in vitro neutralizing , taken before (pre-bleed) or after immunizations, were determined by using insect cell-expressed S1 domain of the SARS-CoV S as the capture antigen. Sera from two mice were pooled after challenge and analyzed. Thin and thick arrows depict times of immunizations and challenge with SARS-CoV, respectively. (B) Prechallenge SARS-CoV neutralization titers of pooled serum were determined. The dilution of serum that completely prevented SARS-CoV cytopathic effect in 50% of the wells was calculated. Statistical comparison of MVA͞S titers to unvaccinated controls was performed by using a Mann-Whitney U nonparametric analysis; activity were described (29) , and it will be interesting to test them in vivo.
No enhanced virus replication or obvious disease was found in mice that were immunized with MVA͞S before challenge with SARS-CoV, as has been found after immunization with a vaccinia virus vector expressing S from feline infectious peritonitis virus and challenge with the corresponding virus (30) . The latter effect is thought to be due to S antibody-dependent enhanced infection of macrophages (31, 32) . Although it will be necessary to look for enhanced antibody effects in other animal models of SARS-CoV, the present study is encouraging for the development of SARS-CoV vaccines based on the highly attenuated MVA vector expressing S. Virus not detected; the lower limit of detection of infectious virus in a 5% wt͞vol suspension of nasal turbinates was 1.8 log10 TCID50 per g and in a 10% wt͞vol suspension of lung homogenate was 1.5 log 10 TCID50 per g.
